Top

Published in:

Open Access 20-06-2022 | Literatur kommentiert

Wöchentliche versus dreiwöchentliche Cisplatingabe bei der postoperativen Radiochemotherapie von lokal fortgeschrittenen Kopf-Hals-Plattenepithelkarzinomen – Ergebnisse der JCOG1008-Studie

Authors: Dr. Alexander Rühle, Prof. Dr. Dr. Nils H. Nicolay

Published in: Strahlentherapie und Onkologie | Issue 10/2022

Auszug

Sowohl in der definitiven als auch in der postoperativen Situation stellt die dreiwöchentliche Administration von 100 mg/m² Cisplatin aufgrund einer Vielzahl prospektiver Phase-III-Studien den Goldstandard bei einer Radiochemotherapie (RCT) lokoregionär fortgeschrittener Kopf-Hals-Plattenepithelkarzinome (LA-HNSCC) dar. In der klinischen Praxis wird aufgrund der besseren Steuerbarkeit und der geringeren Akuttoxizität oftmals auf das wöchentliche Schema mit 30–40 mg/m² Cisplatin zurückgegriffen, obgleich die Evidenz für eine onkologische Äquivalenz beider Schemata strittig ist. Die JCOG1008-Studie, eine multizentrische Phase-II/III-Studie, prüfte daher die Nichtunterlegenheit der wöchentlichen Gabe von 40 mg/m² Cisplatin gegenüber dem etablierten dreiwöchentlichen Schema in der postoperativen Situation. …

Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T et al (2022) Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial. J Clin Oncol. https://doi.org/10.1200/JCO.21.01293

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952CrossRef

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944CrossRef

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF et al (2013) Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845–852CrossRef

Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL et al (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–1161CrossRef

Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V et al (2017) Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 22:1056–1066CrossRef

Tsan DL, Lin CY, Kang CJ, Huang SF, Fan KH, Liao CT et al (2012) The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol 7:215CrossRef

Bauml JM, Vinnakota R, Park AYH, Bates SE, Fojo T, Aggarwal C et al (2019) Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck. J Natl Cancer Inst 111:490–497CrossRef

Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A et al (2018) Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 36:1064–1072CrossRef

10.

Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr., Bossi P et al (2016) Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck 38(Suppl 1):E2151–E2158CrossRef

11.

Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D et al (2014) Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 32:3858–3866CrossRef

12.

Spreafico A, Huang SH, Xu W, Granata R, Liu C‑S, Waldron JN et al (2016) Impact of cisplatin dose intensity on human papillomavirus-related and-unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer 67:174–182CrossRef

13.

Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393:40–50CrossRef

14.

Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393:51–60CrossRef

15.

Haehl E, Rühle A, Spohn S, Sprave T, Gkika E, Zamboglou C et al (2021) Patterns-of-care analysis for radiotherapy of elderly head-and-neck cancer patients: a trinational survey in Germany, Austria and Switzerland. Front Oncol 11:723716CrossRef

Title: Wöchentliche versus dreiwöchentliche Cisplatingabe bei der postoperativen Radiochemotherapie von lokal fortgeschrittenen Kopf-Hals-Plattenepithelkarzinomen – Ergebnisse der JCOG1008-Studie
Authors: Dr. Alexander Rühle
Prof. Dr. Dr. Nils H. Nicolay
Publication date: 20-06-2022
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 10/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-01970-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Wöchentliche versus dreiwöchentliche Cisplatingabe bei der postoperativen Radiochemotherapie von lokal fortgeschrittenen Kopf-Hals-Plattenepithelkarzinomen – Ergebnisse der JCOG1008-Studie

Auszug

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 10/2022

Risikostandardisierte Mortalitätsraten übertreffen als Qualitätsindikator die typischen „Mindestzahlen“ in der onkologischen Chirurgie – ein neuer Blick auf Krankenhauszentralisationen mithilfe nationaler bevölkerungsbezogener Daten

Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO)

Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy

Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors

Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study

DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis